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Abstract
Mutation of the West Nile virus-like particle (WN VLP) prM protein (T20D, K31A, K31V, or 
K31T) results in undetectable VLP secretion from transformed COS-1 cells. K31 mutants formed 
intracellular prM-E heterodimers; however these proteins remained in the ER and ER–Golgi 
intermediary compartments of transfected cells. The T20D mutation affected glycosylation, 
heterodimer formation, and WN VLP secretion. When infectious viruses bearing the same 
mutations were used to infect COS-1 cells, K31 mutant viruses exhibited delayed growth and 
reduced infectivity compared to WT virus. Epitope maps of WN VLP and WNV prM were also 
different. These results suggest that while mutations in the prM protein can reduce or eliminate 
secretion of WN VLPs, they have less effect on virus. This difference may be due to the quantity 
of prM in WN VLPs compared to WNV or to differences in maturation, structure, and symmetry 
of these particles.
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Introduction
West Nile virus (WNV) is an emerging global pathogen causing WN fever and 
meningoencephalitis. Since its introduction into the Western Hemisphere in 1999 it has 
spread throughout North and Central America and the Caribbean and currently is the leading 
cause of mosquito-borne human encephalitis in the region (Mackenzie et al., 2004). WNV is 
a member of the family Flaviviridae, genus Flavivirus. It is maintained in an enzootic cycle 
between mosquitoes and birds with humans and other mammals as incidental hosts 
(Mackenzie et al., 2004). Other medically important flaviviruses include Japanese 
encephalitis virus (JEV), tick-borne encephalitis virus (TBEV), yellow fever virus, and the 
four serotypes of dengue viruses (DENV).
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WNV has a single-stranded, positive sense 11 kb RNA genome that encodes 3 structural 
proteins at its 5′-end. The envelope (E) protein is the major virion glycoprotein responsible 
for virus membrane attachment and fusion. The capsid (C) protein binds the genomic RNA 
to form the nucleocapsid. The pre-membrane (prM) protein is a chaperone that assists in the 
maturation of the E protein, and occurs as a prM-E heterodimer. The prM-E heterodimers 
form 60 trimeric spikes on the surface of the immature DEN2 virion that measures 600 Å in 
diameter (Li et al., 2008). The pr peptide is the amino terminal part of the prM protein that is 
cleaved from prM during virion maturation by the host multibasic-recognition protease 
furin. The pr remains associated with the virion to protect the fusion loop of the E protein 
from premature fusion until reaching an extracellular neutral pH environment. Once the 
virion reaches a neutral pH, the pr peptide dissociates, resulting in the formation of a fusion-
competent particle (Yu et al., 2009). Since this cleavage by furin can be inefficient, and 
appears to be host-cell dependent, not all virions released from cells contain mature M and 
in fact, there is likely populations of virions containing M, prM or a mixture of prM and M 
on the virion surface as demonstrated by cryo-electron microscopy (Cherrier et al., 2009; 
Junjhon et al., 2010; Pokidysheva et al., 2006; Zhang et al., 2003). The existence of prM in 
infectious flavivirus particles has also been established with experiments measuring pH 
sensitivity, viral tropism and neutralization capacity of antibodies with less accessible sites 
on E when prM is present (Davis et al., 2006; Guirakhoo et al., 1992; Nelson et al., 2008).
The polyprotein encoded by the flavivirus RNA genome is translated in association with the 
rough endoplasmic reticulum (ER). Several transmembrane domains of the polyprotein 
traverse the ER membrane and co- and post-translational cleavages to produce functional 
products are carried out by the host enzyme signalase and the virally-encoded protease 
NS2B-3 (Lindenbach and Rice, 2003). The viral structural proteins prM and E form dimers 
on the ER membrane, producing an icosahedral scaffold that may or may not enclose the 
viral RNA genome packaged in the nucleocapsid (Konishi et al., 1992; Schalich et al., 
1996). The virus particles acquire their lipid bilayer envelopes as they bud into the lumen of 
the ER and are transported through the Golgi for further envelope protein modification, 
including glycosylation of the structural proteins and cleavage of the pr peptide from the 
prM protein by host furin protease. Virus particles contained in vesicles are released from 
the cell through the exocytic pathway (Mackenzie and Westaway, 2001).
Recent studies have shown the importance of the prM protein in the maturation and 
secretion of virions and VLPs. Tan et al. (2009) showed that the highly conserved tyrosine at 
amino acid (AA) residue 78 in the ectodomain of the prM protein of WNV is essential for 
virus assembly and secretion from cells (Tan et al., 2009). The H99 residue in the prM 
protein of JEV, positioned opposite from hydrophobic surfaces on the E protein, was shown 
to be critical in the formation of prM-E heterodimers. The transition to neutral pH may 
change interactions between amino acids at this prM-E interface, leading to release of pr and 
formation of mature virions (Li et al., 2008). Yoshii et al. (2004) found that mutating the 
prM P63 to a serine greatly reduced the production of VLPs and virions of TBEV (Yoshii et 
al., 2004). This AA lies in the pr region of the prM protein that is conserved in flaviviruses 
and was shown to be crucial in the formation of prM-E heterodimers (Yoshii et al., 2012). 
The loss of the N-linked glycosylation site in the pr portion of JEV prM protein results in a 
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20-fold decrease in infectious virion production and decreased virulence in mice inoculated 
peripherally with mutant virus (Kim et al., 2008).
In order to map the epitope binding of 3 fully human monoclonal antibodies (hMAbs), we 
made four mutations (T20D, K31A, K31V, K31T) in the prM protein of the WN VLP that 
resulted in failure to secrete VLP antigen from transfected cells (Calvert et al., 2011). 
Although VLPs were not secreted as a result of these mutations, prM antigen was detected 
in the transfected COS-1 cells. In this report we examine the effects of these prM mutations 
on WN VLP assembly and secretion as well as on infectious virus replication and protein 
expression.
Results
Mutations in WNV prM protein affect secretion of VLP
Previously, we constructed WN VLP mutants to identify the epitopes on the prM protein 
recognized by 3 virus-specific hMAbs (Calvert et al., 2011). All three of the mutations made 
at K31 in the prM protein (K31A, K31T, K31V) resulted in significantly reduced secretion 
of VLP. Another mutation, T20D had the same effect on VLP secretion. These mutations 
occurred in AA residues that are located on the surface-exposed face of pr and did not 
appear to be involved in interactions with the E protein in prM-E heterodimers or disulfide 
bonds in the prM protein (Li et al., 2008).
To investigate the effects of these mutations on VLP secretion, COS-1 cells were transfected 
with WT and mutant (T20D, K31A, K31T, and K31V) pVAXWN plasmids, cell culture 
supernatant was harvested on days 2 and 7 post-transfection, and detection of viral proteins 
was performed by antigen-capture ELISA, using polyclonal rabbit serum to WNV prM and 
E proteins as capture antibody and mouse hyperimmune ascitic fluid (MHIAF) to WNV as 
detector antibody. Transfected cells were incubated at 37 °C up to 7 days. Detection of 
secreted prM and E proteins was reduced significantly for all prM mutants at day 2 and day 
7 compared to WT using Dunnett’s method of multiple comparisons with an overall type I 
error of 0.05 (Fig. 1). We also conducted experiments in which cells were incubated for the 
first 6 h at 37 °C and then transferred to 28 °C for 7 days, and similar results as those shown 
above were obtained (data not shown). These data indicate that K31 and to some extent T20 
may play important roles in WN VLP secretion.
Effect of mutations in VLP prM on prM-E heterodimerization
During flavivirus assembly prM and E proteins form heterodimers that interact with the 
nucleocapsid and bud through the ER membrane to form immature virus particles. Co-
expression of prM with E is necessary for correct folding of the E protein; however, prM is 
able to form its native structure in the absence of E protein (Konishi and Mason, 1993; 
Lorenz et al., 2002). To determine if the mutations in prM disrupted prM-E 
heterodimerization during formation of VLPs, COS-1 cells transfected with WT and prM 
mutant pVAXWN plasmids were lysed, prM and E proteins were immunoprecipitated with 
either anti-E or anti-prM MAb, and precipitated viral proteins were detected by immunoblot 
(Fig. 2). When VLPs were immunoprecipitated with the anti-prM hMAb 8G8, the E protein 
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was co-precipitated and detected in all cell lysates transfected with WT and mutant 
plasmids. (Fig. 2B). Interestingly, prM protein from the T20D mutant was detected as a 
doublet corresponding to the glycosylated and non-glycosylated forms of the protein. When 
VLPs were immunoprecipitated with the anti-E mMAb 3.91D, prM protein was detected in 
co-precipitate from lysates of cells transfected with WT and K31A, K31T and K31V mutant 
plasmids but apparently not with T20D mutant plasmid. When the concentration of lysate 
from cells transfected with T20D pVAXWN plasmid was increased 2-fold in the 
immunoprecipitation reaction a very small amount of non-glycosylated prM was detected 
(Fig. 2B). These results suggest that heterodimerization of the E and prM protein is not 
affected by mutations at K31, but is affected by the T20D mutation on the prM protein. The 
mutation at T20 permits production of both glycosylated and non-glycosylated forms of 
prM, and only the non-glycosylated form of the protein appears to associate with the E 
protein.
To confirm that the T20D mutation resulted in production of both glycosylated and non-
glycosylated forms of prM, and that glycosylation of the E and prM proteins was not 
affected by the K31 mutations, prM and E proteins were immunoprecipitated from cell 
lysates and digested with the endoglycosidase, PNGaseF, which cleaves all types of N-
linked of multiple glycans. The migration patterns of treated and non-treated samples were 
compared (Fig. 3A). The E protein from WT and prM mutants was shown to be glycosylated 
as indicated by an apparent shift in mobility from 54 kDa to 50 kDa. The prM proteins 
expressed from WT and K31 mutant plasmids were also shown to be glycosylated as 
indicated by a shift in mobility from 20 kDa to 17 kDa. PNGaseF digestion also confirmed 
that the prM doublet seen in the lysate from cells expressing the T20D mutant was due to 
expression of both glycosylated and non-glycosylated forms of the protein since only the 
smaller band (17 kDa) was visible after digestion. To determine the form of the 
carbohydrates on prM and E immunoprecipitated proteins were digested with 
endoglycosidase H (EndoH), an enzyme which cleaves the chitobiosyl unit of the high 
mannose form of the carbohydrate on the glycoprotein. Migration patterns of EndoH treated 
and untreated samples were compared (Fig. 3B). The E and prM glycoproteins of WT and 
mutants were shown to be sensitive to EndoH digestion indicating that in cells the 
glycoproteins were predominately in high mannose form. Processing of high mannose 
carbohydrates to the complex form takes place in the Golgi, therefore, since these protein 
still contained the high mannose form of the carbohydrate they must localize to the ER. The 
overall decrease in prM and E protein concentrations from T20D compared to WT may 
reflect the inability of this construct to assemble heterodimers. Since the K31 mutants 
expressed equal amounts of prM and E proteins in transfected cells as WT, these contructs 
may be able to form stable prM-E heterodimers but unable to form stable particles that can 
interact with cellular factors for efficient release from cells.
Mutations in WNV prM protein affect cellular localization of viral proteins
The immunoprecipitation results indicated that intracellular prM-E heterodimers are formed 
with the K31 prM mutants and to a much lesser extent with the T20D prM mutant, however, 
as shown previously, the VLPs are not secreted. Therefore, the block in secretion must occur 
in a later step in replication. During assembly, flaviviruses bud into the ER lumen of virus-
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infected cells and are transported to the Golgi for subsequent processing (Lindenbach and 
Rice, 2003). To determine whether the prM mutations had an impact on the distrubution of 
viral proteins inside the cell, COS-1 cells transfected with WT and prM mutant pVAXWN 
plasmids were fixed at 6, 12, 24 and 48 h post-transfection, permeabilized and double 
stained with antibodies to detect E protein (mMAb 3.91D), and either ER (anti-calreticulin), 
coatomer (anti-βCOP I), ER-Golgi intermediate compartment (anti-ERGIC53) or Golgi 
(anti-GRASP65) markers (Fig. 4). At 6 h E protein expressed by WT and prM mutant 
plasmids coincided with ER, and ERGIC markers, with some coincidence with βCOPI and 
no coincidence with Golgi (data not shown). In WT transfected cells at 12 h post-
transfection the distribution of the E protein completely coincided with the ER and ERGIC, 
and to some extent with the Golgi (Fig. 4A). At 24 h post-transfection WT E protein 
completely coincided with ER and ERGIC markers while moderate coincidence of E protein 
with the Golgi marker was observed (Fig. 4B). Staining of cells transfected with T20D 
mutant had simliar staining to WT. At 12 h post-transfection distrubution of the E protein 
completely coincided with the ER and ERGIC markers, with moderate coincidence with 
Golgi marker; however, unlike WT, T20D E protein also conincided with βCOPI marker 
(Fig. 4A). At 24 h postransfection distribution of the E protein expressed from the T20D 
mutant moderately coincided with ER and ERGIC markers with less coincidence with 
βCOPI marker and no coincidence with Golgi marker (Fig. 4B).
Distribution of the E protein expressed by the K31 mutants in transfected cells appeared to 
be different from WT. Moderate coincidence of E protein with βCOPI and Golgi markers 
and complete coincidence with ER and ERGIC markers were observed in cells transfected 
with K31 mutant plasmids at 12 h post-transfection (Fig. 4A). At 24 h post-transfection the 
E protein expressed by K31 mutants coincided with ER, ERGIC and somewhat with βCOPI 
markers. Staining of E protein expressed by K31 mutants and Golgi marker was not 
colocalized at 24 h (Fig. 4B). At 48 h E protein expressed by WT and prM mutant plasmids 
coincided with ER, βCOPI, and ERGIC markers. Unlike WT which did not co-localize with 
Golgi at 48 h, E protein expressed from K31 mutants coincided somewhat with Golgi 
marker (data not shown).
The most stricking result was the extremely concentrated and localized distribution of the E 
protein in cells expressing K31 mutants compared to the staining of the E protein from cells 
transfected with WT plasmid. These observations suggest that mutations at K31 in the prM 
protein result in an accumulation of E protein in the ER, ER–Golgi intermediary 
compartments and to some extent the Golgi complex, possibly due to the inability of these 
mutant prM-E heterodimers to effectively interact with unknown cellular factors in order to 
be secreted from the cell.
Effect of mutations in prM protein on virus replication
To determine if these prM VLP secretion-blocking mutations had an effect on virus 
maturation and release, the same mutations were introduced into an infectious cDNA clone 
of the WNV genome. C6/36 cells were transfected with in vitro transcribed, mutant WNV 
RNA and virus was harvested 7 days after transfection. Virus and viral RNA production 
were measured by plaque assay and quantitative RT-PCR (qRT-PCR). The prM and E genes 
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of WT and mutant virus RNA were sequenced on day 0 and day 7, and the introduced 
mutations were found to be present with no compensatory mutations identified. Growth 
characteristics of viruses were determined in one mosquito cell line (C6/36) and two 
mammalian cell lines (Vero and COS-1) by infecting cells at a multiplicity of infection 
(MOI) of 0.1 and analyzing daily medium samples by plaque assay. All 4 prM mutant 
viruses grew similarly to WT in C6/36 cells except for K31T, which had a titer 10-fold lower 
than WT virus from day 1 to day 4 (Fig. 5A). The prM mutant viruses also grew similarly to 
WT virus in Vero cells after day 2; however, all mutant viruses grew more slowly than WT 
between days 0 and 2 (Fig. 5B). Growth of the prM mutant viruses as compared to WT were 
most different in COS-1 cells. While K31V grew similarly to WT virus, T20D, K31A and 
K31T virus titers were about 10-fold lower (Fig. 5C). Average plaque sizes in Vero cells of 
prM mutant viruses harvested from these growth studies were compared to WT virus. No 
significant difference between T20D and WT plaque sizes was seen in viruses grown in any 
cell type. Average plaque sizes for K31A and K31T were significantly smaller compared to 
WT for viruses obtained from all three cell lines. The average plaque sizes were significantly 
less only for the K31V mutant obtained from C6/36 cells (Table 1). These results indicate 
that while virus growth was delayed, and plaque sizes were reduced in Vero cells compared 
to WT virus, the prM mutant viruses were able to overcome deleterious effects and replicate 
in all three cell types.
Since the prM mutants did not show significant differences from WT virus growth in all cell 
culture types we determined the viral RNA-to-pfu ratio of the mutants to assess the presence 
of defective particles and infectious virus compared to WT. Infectious virus titers in cell 
culture medium were determined when peak WT titer was achieved (C6/36 and COS-1 cells, 
day 4; Vero cells, day 2) by plaque assay, and extracellular RNA in the same samples was 
measured by qRT-PCR. The ratio of RNA copies/ml to PFU/ml for mutant viruses was 
compared to WT virus in each cell type and results are shown in Fig. 6. In C6/36 cells there 
was only a significant difference in the ratio of RNA copies/ml to PFU/ml for the K31V 
mutant compared to WT. WT virus produced 1.4 times more RNA copies/ml than PFU/ml, 
while the T20D, K31A, K31T and K31V mutants produced 2.4, 6.3, 7.2 and 15.4 times 
more RNA copies/ml than PFU/ml, respectively (Fig. 6A). None of the mutants had 
significantly higher ratios of RNA copies/ml than PFU/ml when compared to WT in Vero 
cells. WT virus produced 22 times more RNA copies/ml than PFU/ml in Vero cells, while 
T20D, K31A, K31T and K31V mutants produced 26, 49, 57 and 32 times more RNA 
copies/ml than PFU/ml, respectively (Fig. 6B). In COS-1 cells the T20D, K31T and K31V 
mutants had significantly higher ratios of RNA copies/ml to PFU/ml compared to WT virus. 
WT virus produced 15 times more RNA copies/ml than PFU/ml and T20D, K31A, K31T 
and K31V produced 236, 29, 45 and 51 times more RNA copies/ml than PFU/ml, 
respectively (Fig. 6C). These results indicate that in COS-1 cells, the T20D, K31T and 
K31V prM mutations resulted in less efficient production of infectious virus, and growth of 
the K31V mutant in C6/36 cells was less efficient in infectious virus production than WT 
virus.
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Effect of prM mutations on hMAb binding to virions
Previously, the binding of hMAbs to WN VLP epitopes was characterized, showing that V19 
and L33 were key amino acid residues in the VLP epitope recognized by all three hMAbs 
(Calvert et al., 2011). Since the prM mutations (T20D, K31A, K31T and K31V) prevented 
secretion of VLP, binding could not be tested in ELISA. Therefore, these mutations, along 
with 9 other mutations (V19A, V19N, V19T, T20A, T20Q, T24A, L33A, L33K, L33Q) in 
the pr peptide found to have significant effects on hMAb binding, were incorporated into the 
WNV infectious cDNA clone (Calvert et al., 2011). In vitro-transcribed RNA was 
transfected into C6/36 cells, and virus was harvested 7 days later. Introduced mutations were 
confirmed by sequencing of the prM and E genes, and virus titer was determined by plaque 
assay. COS-1 cells were infected with all prM mutant WNVs at an MOI of 0.1 to produce 
virus for antigen-capture ELISA to test hMAb binding. COS-1 derived virus was used in the 
assay in order to directly compare hMAb binding to previous results with VLPs secreted 
from transfected COS-1 cells. Human sera positive for anti-flavivirus antibody was used as a 
control in the ELISA to validate that the concentrations of viral proteins were uniform for all 
mutant viruses tested. Fold changes in reactivity with the control sera range from 0 to 2 and 
indicate that virus preps used in the ELISA contained comparative concentrations of viral 
proteins.
The only mutations that resulted in a significant reduction in reactivity with hMAb 8G8 
were K31A and K31V, with 5- and 4-fold reductions of end-point titers, respectively. The 
T20D mutation resulted in a 10-fold increase in reactivity with hMAb 8G8. All other 
mutations in the pr peptide of WNV resulted in 3-fold or less reduction in hMAb end-point 
titers, which was not considered significant (Table 2). These results suggest that the K31 AA 
residue in virion prM may be important in the binding of hMAb 8G8.
Discussion
Recent research on the functional importance of the prM protein in flavivirus infections has 
revealed that the protein is not only important for viral structure and assembly, but also plays 
an important role in infection and immunity. New evidence shows that non-neutralizing 
antibodies to prM can enhance DENV infection of Fc receptor-bearing cells in vitro as well 
as enhance WNV infection in vivo (Colpitts et al., 2011; Huang et al., 2008, 2006). These 
anti-prM antibodies may assist immature virus particles in cell entry, thereby increasing the 
number of virus-producing cells in secondary infections (Dejnirattisai et al., 2010; 
Rodenhuis-Zybert et al., 2010). The prM protein of flaviviruses also plays an important role 
as a chaperone to the major envelope glycoprotein E. Not only is the prM protein required 
for proper folding and maturation of the E protein during virus assembly, it also protects the 
fusion loop on the E protein from premature fusion before exiting the cell (Konishi and 
Mason, 1993; Lorenz et al., 2002; Yu et al., 2009). Recently, the prM protein of DENV has 
been shown to associate with members of the ADP-ribosylation factor (Arf) family of 
proteins (Kudelko et al., 2012; Wang et al., 2009). These host cellular factors are known to 
play a critical role in intracellular trafficking as well as modulating membrane curvature, a 
function critical to the assembly and budding of flaviviruses from the ER membrane (Beck 
et al., 2008; Garoff et al., 1998). The prM protein of DENV was also shown to interact with 
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vacuolar-ATPases (V-ATPases) in infected cells. These enzymes acidify intracellular 
organelles, including those in the secretory pathway, and pump protons across the plasma 
membrane of the cell. This interaction could be significant in both virus entry and membrane 
fusion via acidified endosomes and secretion of newly assembled virus particles out of the 
cell (Duan et al., 2008).
In the present study, we describe the effects of 4 specific mutations in the WNV prM protein 
on WN VLP secretion. Mutations made in prM K31 and T20 in the prM expressed from the 
pVAXWN plasmid resulted in a loss of VLP secretion from transfected COS-1 cells. While 
K31 mutants were shown to efficiently form prM-E heterodimers, VLP particle secretion 
was blocked, resulting in accumulation of viral proteins in the ER, ER–Golgi intermediary 
compartments and to some extent in the Golgi of transfected cells.
Assembly and maturation of viral particles begins at the membrane of the ER. The prM and 
E proteins dimerize and then form an icosahedral scaffold that leads to budding of the 
enveloped particles into the lumen of the ER. These virus particles are transported through 
the Golgi and released from the cell via the exocytic pathway; however, the exact details of 
this process are poorly characterized (Mackenzie and Westaway, 2001; Welsch et al., 2009). 
Flaviviruses have been shown to associate with calnexin and calreticulin, lectins found in the 
ER that assist in the proper folding of glycoproteins, chaperoning them through the ER and 
retaining incompletely folded proteins (Courageot et al., 2000; Lorenz et al., 2003; 
Mackenzie and Westaway, 2001; Wu et al., 2002). Arf proteins have been implicated in 
DENV VLP trafficking from the ER to the Golgi since depletion of Arf1, Arf4 and Arf5 
resulted in blocking secretion of VLPs and virions (Kudelko et al., 2012; Wang et al., 2009). 
In fact, the prM protein was found to interact with these cellular factors, which may be 
crucial in the trafficking and secretion of virus particles through the cell. While all four 
DENVs and YFV were shown to produce less virus when these proteins were down-
regulated in the infected cell, this had no effect on WNV infection and secretion (Kudelko et 
al., 2012). This descrepancy may be due to differences in the two viral particle systems 
studied, or it may be due to an inconsistency of the role of these cellular proteins in 
flavivirus maturation and secretion.
Interestingly, the epitope containing K31 in the prM protein is positioned at the top of the 
prM-E trimer spike in immature virus particles (Fig. 7A). These mutations had no effect on 
prM-E heterodimer formation and protein glycosylation, and appear to play no role in 
stabilization of trimer spike formation. Since its role in virus assembly does not appear to be 
structurally-related, we can hypothesize that it must play some role in interacting with host 
cellular factors in trafficking the particles through the ER, Golgi and ultimately out of the 
cell. L33 was previously mutated in the WN VLP to an alanine, lysine, glutamine and 
threonine and had no effect on VLP secretion (Calvert et al., 2011). This epitope is not 
positioned as prominently on the top of the prM-E trimer spike as K31 (Figs. 7A and B). It 
is also interesting that the K31 AA residue is sandwiched between two highly conserved 
residues among flaviviruses, G30 and N32, which may indicate that this region of prM plays 
some critical role for prM structure and function.
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The T20D mutation in the prM protein resulted in failure to form the prM-E heterodimer 
containing glycosylated prM as shown by immunoprecipitation studies of lysates from cells 
transfected with the mutated plasmid. The T20D mutation caused inefficient glycosylation 
of the prM protein, and interestingly only small amounts of non-glycosylated T20D prM 
were shown to associate with the E protein (Fig. 2B). The plasmid with T20D mutation also 
expressed glycosylated prM in COS-1, but they were not associated with E protein. 
Glycosylation of the E protein of flaviviruses has been studied extensively and shown to be a 
critical factor in flavivirus replication, maturation and neuroinvasiveness in mice (Beasley et 
al., 2005b; Lad et al., 2000; Li et al., 2006; Scherret et al., 2001). Glycosylation of the prM 
protein has also been shown to be important for heterodimer formation and secretion of viral 
proteins from the cell. In JEV, glycosylation of the prM protein was shown to be an 
important factor in virion assembly and release as well as viral pathogenicity in mice (Kim 
et al., 2008). Deletion of the prM glycosylation site resulted in a reduction of secreted TBE 
and WN VLPs (Goto et al., 2005; Hanna et al., 2005). The T20 AA residue lies in close 
proximity to the glycosylation site on the prM protein in WNV at N15-X16-T17 (Fig. 7B). 
While the mutation does not directly affect the sequence of the glycosylation site, mutating 
the small hydrophilic AA residue threonine to a large negatively charged AA residue 
aspartic acid could affect the local biochemistry of the region which in turn could prevent 
effective glycosylation of the prM in the heterodimer structure and/or destabilize 
heterodimers containing the glycosylated T20D prM. Likewise, each of the prM-E 
heterodimers may be affected by the T20 residues in the other two prM proteins in close 
proximity in the prM-E trimer spike (Fig. 7B). Previously, mutations made at this AA 
residue (A, G, Q) and those made at AA residue V19 (A, N, R, T) had no effect on VLP 
secretion (Calvert et al., 2011).
While these mutations had significant effects on VLP secretion, their effect on virus 
replication was measurable, but not as dramatic. K31 mutants replicated reasonably well in 
the three cell types tested (C6/36, COS-1 and Vero cells), with a few exceptions. The K31T 
mutant replicated more slowly in C6/36 cells than WT or the other prM mutant viruses, 
while in Vero cells all the mutants replicated more slowly than WT before day 2 post-
infection. In contrast, K31V was the only mutant to replicate similarly to WT virus in 
COS-1 cells. Comparisons of plaque morphology revealed that all K31 mutants obtained 
from any of the three cell types (except for K31V from COS-1 cells) produced significantly 
smaller plaques than WT viruses in Vero cells, indicating a replication defect. In 
comparisons of the amount of extracellular virus RNA (presumably packaged in defective 
particles) to infectious virus particles, the K31V mutant produced significantly higher ratios 
of RNA to infectious virus than WT virus in C6/36 and COS-1 cells, while the K31T mutant 
only produced significantly higher ratios of RNA to infectious virus than WT virus in 
COS-1 cells. The T20D mutant also produced higher ratios of RNA to virus than WT virus 
in COS-1 cells. While the differences in production of VLP and virus particles with these 
mutations are surprising, it is not unprecedented. TBE VLP secretion was inhibited by a 
mutation at prM AA residue 63 from a proline to a serine; however, when this same 
mutation was incorporated into the virus genome, only a 10-fold decrease in titer over the 
first 48 h of replication was documented (Yoshii et al., 2004). Likewise, when mutations in 
JEV ablated glycosylation of the prM protein, virus particles continued to be produced, 
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although at a 20-fold decreased titer from WT (Kim et al., 2008). Taken together, these 
studies demonstrate that mutations that affect VLP formation and secretion may not 
completely have the same effects on virions. This observation is important to consider when 
using VLPs to study virus structure and function, and significant findings should be 
confirmed with replicating virus.
Epitope mapping with hMAbs to the WNV WT and mutant prM proteins revealed a large 
disparity between VLP and virion presentation of the prM protein. This may be due to the 
relative concentrations of prM present in the two systems, or to the presentation of the 
protein itself and the accessibility of the epitopes recognized by these hMAbs. 
Concentrations of VLPs were standardized by optical density in an ELISA designed to 
detect all prM and E proteins in the supernatant. Virions were standardized by PFU/ml titers, 
and viral protein concentrations were validated with the inclusion of polyclonal anti-
flavivirus human sera. TBE VLP which only contains M is the only VLP structure to be 
solved of the flaviviruses, therefore it is difficult to compare the unknown structure of the 
WN VLP with the resolved structure of the mature and immature flavivirus particle 
(Ferlenghi et al., 2001; Kuhn et al., 2002; Zhang et al., 2003). While differences between 
virus- and VLP-expressed E protein do not appear to affect epitope expression, differences 
in protein arrangements between VLP, mature and immature virions could account for 
differences in epitope recognition on the prM protein by the hMAbs in our study. We are 
currently conducting co-crystallization studies to elucidate binding of virions by hMAbs.
This study reiterates the importance of the prM protein in maturation and assembly of VLP 
and virions and highlights a structural region that has not been previously shown to be 
important for particle maturation and secretion. The K31 AA residue in the prM protein of 
WNV has a significant impact on WNV particle assembly and secretion processes. Further 
investigation into the specific role of the prM protein and the critical epitopes involved will 
be needed to understand the process of intracellular trafficking of virus.
Materials and methods
Cells
C6/36 (Aedes albopictus mosquito), Vero (African green monkey kidney) and COS-1 
(African green monkey kidney) cells were cultured as described previously (Davis et al., 
2001; Huang et al., 2000). Cells were maintained in DMEM (Invitrogen) supplemented with 
10% fetal bovine serum (FBS), 2 mM L-glutamine, 110 mg/L sodium pyruvate, 0.1 mM 
nonessential amino acids, 20 ml/L 7.5% sodium bicarbonate and penicillin (100 U/ml)/
streptomycin (100 µg/ml). Vero and COS-1 cells were grown at 37 °C with 5% CO2 while 
C6/36 cells were grown at 28 °C with5% CO2.
Antibodies
The anti-prM MAbs 8G8 and 5G12 (a kind gift from I. Trakht and G. Kalantarov, Columbia 
University) are WNV specific hMAbs reacting to AA residues V19 and L33 in the prM 
protein of the VLP (Calvert et al., 2011). Anti-E MAbs 3.91D and 3.67G were obtained 
from the Arbovirus Diagnostic and Reference Collection activity, DVBD/ADB. These MAbs 
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used in the immunoprecipitation studies are WNV specific mMAbs reacting to AA residues 
S306, K307 and T332 in DIII of the E protein (David C. Clark, unpublished data).
Site-directed mutagenesis and production of mutant infectious WNV and WN VLP
The WNV two-plasmid infectious clone (WN-IC) and pVAXWN plasmid were utilized to 
produce WNV and VLP respectively, as previously described (Beasley et al., 2005a; Davis 
et al., 2001; Kinney et al., 2006). Site-specific mutations were introduced into the prM gene 
of both systems using the QuikChange site-directed mutagenesis kit (Stratagene). Mutagenic 
primer sequences used for all constructs and transient expression of WN VLP in COS-1 
cells by pVAXWN electroporation have been previously described (Calvert et al., 2011). 
Electroporated COS-1 cells were recovered in 6 ml of DMEM supplemented with 10% FCS. 
Cells were seeded into 25-cm2 culture flasks for VLP expression and incubated at 37 °C 
with 5% CO2. Six hours after electroporation, the growth medium in flasks was replaced 
with DMEM containing 2% FCS. Tissue culture medium were harvested 2 and 7 days after 
electroporation for determination of VLP secretion by ELISA.
Once full length WN-IC cDNA was obtained, in vitro transcription of RNA was carried out 
as previously described (Kinney et al., 2006). C6/36 cells were transfected with transcribed 
RNA by electroporation. Transfected cells were incubated at 28 °C/5% CO2 for 7 days at 
which point supernatant was harvested and infectious virus titers were determined by plaque 
assay. The prM and E genes of WT and mutant viruses were sequenced, and the correct 
mutations were found to be present in all mutant viruses with no compensatory mutations 
present.
Characterization of WN-IC mutant viruses in culture
Viral growth curves were performed in triplicate in 6 well plates of Vero, COS-1 or C6/36 
cells at a MOI of 0.1. After adsorption for 1 h, maintenance medium containing 2% FCS and 
penicillin/streptomycin was added and cultures were incubated in 5% CO2 at 37 °C (Vero 
and COS-1 cells) or 28 °C (C636 cells). Aliquots of culture medium were harvested every 
day for 7 days, FCS concentration was adjusted to 20% and aliquots were stored at 80 °C 
prior to titration and RNA extraction. Viral RNA was extracted from virus supernatant with a 
QIAmp Viral RNA kit (Qiagen). WNV-specific primers to the structural genes used were 
based on published data of WNV, strain NY99, and sequencing was carried out as previously 
described (Kinney et al., 2006). Viral RNA was also quantitated at peak viral titers on either 
day 2 for Vero or day 4 for COS-1 and C6/36 cells. A 5 µl aliquot of each sample was added 
to master mix from iScript One-step RT-PCR kit (Bio-Rad) containing 200 nM of probe, 
WN1186F (5′–FAM-TGC CCG ACC ATG GGA GAA GCT C–3′), 200 nM of forward 
primer, WN1160 (5′–TCA GCG ATC TCT CCA CCA AAG–3′) and 200 nM of reverse 
primer, cWN1229 (5′–GGG TCA GCA CGT TTG TCA TTG-3′). WNV-specific RNA was 
tested in triplicate and measured by qRT-PCR using homologous RNA standards on a Bio-
Rad IQ5 Real-time PCR detection system under the following conditions: 50 °C for 30 min, 
95 °C for 15 min, followed by 45 cycles of 94 °C for 15 s, and 57 °C for 1 min with 
continuous fluorescence data collection. Virus plaque titrations were performed under 
double agarose overlay in six-well plates of confluent Vero cells (Huang et al., 2000). The 
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second agarose overlay containing neutral red vital stain was added 4 days after infection, 
and plaques were counted on day 5 after infection.
Analysis of intracellular mutant VLP proteins
Two days after transfection of COS-1 cells with pVAXWN WT and mutant plasmids, cells 
were harvested and cell lysate was produced as previously described (Blitvich et al., 2003). 
Similarly, control antigen was produced with non-transfected COS-1 cells. Viral proteins 
were immunoprecipitated from lysates using the Pierce Immunoprecipitation kit (Thermo 
Scientific) with resin coupled to 75 µg of WNV murine anti-E 3.91D antibody or 75 µg of 
WNV human anti-prM 8G8 antibody following the manufacturer’s in lysates were analyzed 
by digestion after immunoprecipitation using N-glycosidase F (PNGaseF) or 
Endoglycosidase H (EndoH) (New England Biolabs) following the manufacturer’s protocol, 
before analysis by SDS-PAGE.
SDS-PAGE and immunoblotting
WN viral proteins from immunoprecipitated lysates were separated by SDS-PAGE on a 
reduced 4–12% Bis/Tris gel (Invitro-gen). All procedures were performed at room 
temperature. Proteins were blotted electrophoretically from the gels onto nitrocellulose 
membranes and washed for 5 min in PBS/0.1% Tween wash buffer. Non-specific binding 
sites were blocked with 1% BSA/PBS for 1 h while rocking. WNV murine anti-E MAb, 
3.67 G (10 µg), and purified rabbit polyclonal sera to WNV prM (10 µg) (Meridian 
LifeScience) were incubated with the membrane for 1 h with gentle rocking. Membranes 
were washed again in PBS/0.1% Tween wash buffer three times for 5 min each. Goat anti-
mouse antibody and goat anti-rabbit antibody conjugated to alkaline phosphatase (Jackson 
Immunoresearch) were diluted 1:200 and incubated on the membrane for 1 h with gentle 
rocking. Membranes were washed as described previously and BCIP/NBT phosphatase 
substrate (KPL) was added to the membrane until a color change appeared. The reaction was 
stopped by the addition of water.
ELISAs
All ELISAs were performed in 96-well plates (Maxisorp plates, Nunc). To test for secretion 
of mutant VLP antigen, rabbit hyperimmune sera to WNV prM and E proteins was diluted 
1:1000 in carbonate/bicarbonate buffer (50 mM sodium carbonate, 50 mM sodium 
bicarbonate, pH 9.6) and incubated overnight at 4 °C. Plates were washed five times with 
PBS/0.1% Tween wash buffer with an automatic plate washer. Non-specific binding sites 
were blocked with 3% rabbit serum in PBS (100 µl/well) and incubated at 37 °C for 1 h. 
Blocking buffer was removed before supernatant from transfected COS-1 cells was added to 
the plate in doubling dilutions in 3% rabbit serum/PBS (50 µl/well). Antigen was incubated 
at 37 °C for 2 h, after which the plates were washed as previously described. MHIAF to 
WNV was obtained from the Reference Collection of the Diagnostic Laboratory, ADB, 
DVBID, CDC, and used as the primary antibody at a dilution of 1:1600 in 3% rabbit 
serum/PBS and incubated at 37 °C for 1 h. Plates were washed 5 times before the addition of 
rabbit anti-mouse antibody conjugated to horseradish peroxidase (50 µl/well), diluted 1:5000 
in 3% rabbit serum/PBS. After an incubation period of 1 h at 37 °C, plates were washed 
again ten times. Enhanced K-blue TMB substrate (Neogen) was added to each well of the 
Calvert et al. Page 12
Virology. Author manuscript; available in PMC 2018 February 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
plate (100 µl/well) and incubated in the dark at room temperature for 10 min. The reaction 
was stopped with the addition of 1 N H2SO4 (50 µl/well), and the plates were read at 450 nm 
on an automatic plate reader.
To test the reactivity of the mutant viruses with the hMAbs the protocol remained the same 
with some exceptions. Viruses were diluted to a concentration of 106 PFU/ml in 3% rabbit 
serum/PBS. Purified hMAbs were used as the primary antibody and added to the wells in 
two-fold dilutions in 3% rabbit serum/PBS (50 µl/well) starting at 50 µg/ml. The secondary 
MAb, rabbit anti-human conjugated to horseradish peroxidase (50 µl/well) was diluted 
1:5000 in 3% rabbit serum/PBS. The rest of the ELISA was carried out as described above.
Immunofluorescence and confocal microscopy
Transfected COS-1 cells were grown on 8-well chamber slides (Labtek) and incubated in 5% 
CO2 at 37 °C. 48 h after transfection, medium was removed and cells were washed 3 times 
in PBS. Cells were fixed to the slide with 4% (w/v) paraformaldehyde in PBS for 10 min 
and permeabilized with 0.1% (v/v) Triton-X 100 in 0.2% (w/v) BSA/PBS for 10 min. Non-
specific sites were blocked with 10% (v/v) goat serum in PBS for 30 min at 37 °C. Cells 
were incubated with WNV murine anti-E antibody 3.91D (5 µg/ml) and either rabbit anti-
calreticulin (1:500), rabbit anti-βCOP1 (1:100), rabbit anti-ERGIC53 (1:100) or rabbit anti-
GRASP65 (1:500) diluted in PBS for 30 min at 37 °C before being washed 3 times in PBS. 
Secondary antibodies, goat anti-mouse conjugated to FITC and goat anti-rabbit conjugated 
to Texas Red, were diluted 1:100 in PBS and incubated on the cells for 30 min at 37 °C, and 
cells were washed again as previously described. Slides were dried before the addition of 
Prolong Gold anti-fade reagent with DAPI (Invitrogen). Coverslips were mounted on the 
slides and allowed to cure at room temperature overnight. Images were viewed and collected 
with a Carl Zeiss LSM-Pascal confocal microscope.
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Fig. 1. 
Mutations in the prM protein reduce secretion of VLPs. COS-1 cells were transfected with 
wild type (WT) and mutant pVAXWN plasmids. Cell culture supernatant was harvested 2 
(open bars) and 7 (cross-hatched bars) days post-transfection, and prM and E proteins were 
detected by ELISA. Mean absorbance values (±SE) were calculated from two independent 
experiments performed in duplicate. Asterisks indicate statistically significant differences 
compared to WT plasmid using Dunnett’s method of multiple comparisons with an overall 
type I error of 0.05. Control, non-transfected cell control.
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Fig. 2. 
Immunoprecipitation of prM and E proteins in COS-1 cells transfected with mutant VLP. 
COS-1 cells were transfected with WT and mutant pVAXWN plasmids. At 2 days post-
transfection, cells were lysed. Whole cell lysates (A) and lysates immunoprecipitated with 
an anti-E mMAb (3.91D) or an anti-prM hMAb (8G8) (B) were separated by SDS-PAGE on 
a reduced 4–12% Bis–Tris gel and transferred to nitrocellulose membranes. Proteins bands 
were detected using anti-E mMAb (3.67G) and anti-prM rabbit polyclonal sera. Non-
transfected COS-1 cell lysate was used as a control (C).
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Fig. 3. 
Analysis of glycosylation of prM and E proteins in COS-1 cells transfected with mutant 
pVAXWN plasmids. COS-1 cells were transfected with WT and mutant pVAXWN 
plasmids. At 48 h post-transfection, cells were lysed. Lysates were immunoprecipitated with 
an anti-prM hMAb (8G8). Immunoprecipitated proteins were digested with (A) PNGaseF (F
+) or without PNGaseF (F−), and with (B) EndoH (H+) or without EndoH (H−). Proteins 
were separated by SDS-PAGE on a reduced 4–12% Bis–Tris gel and transferred to 
nitrocellulose membranes. Protein bands were detected using anti-E mMAb, 3.67G, and 
anti-prM rabbit polyclonal sera.
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Fig. 4. 
Intracellular localization of expressed E proteins of COS-1 cells transfected with prM 
mutant pVAXWN plasmids. Transfected COS-1 cells expressing pVAXWN WT and prM 
mutant plasmids were fixed 12 (A) and 24 (B) hours post-transfection and stained with 
antibodies against WNV E protein (3.91D) and calreticulin, an ER marker, ER–Golgi 
intermediary complexes βCOP1 and ERGIC53 or GRASP65, a Golgi marker. Co-
localization of the E protein with these marker proteins are depicted in the merged image. 
Nuclei of cells were stained with DAPI and shown in the merged image.
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Fig. 5. 
Virus growth kinetics in C636, Vero, and COS-1cells. C636 (A), Vero (B) or COS-1 (C) 
cells were infected at a MOI of 0.1 and virus titers were measured by plaque assay every day 
for 7 days. Bold line indicates assay limit of detection. Standard error bars are shown for 
days 4 and 6. The data shown are from two independent experiments.
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Fig. 6. 
Viral RNA:PFU Ratio of prM mutants. Virus was grown in C636 (A), Vero (B), or COS-1 
(C) cells and virus supernatant was harvested on days of peak virus titer. RNA was extracted 
and RNA copies/ml was determined by qRT-PCR. Virus titer was determined by plaque 
assay. The number of RNA copies/ml was divided by the virus titer to obtain the ratio of 
RNA copies/ml to PFU/ml. Asterisks indicate statistically significant differences compared 
to WT virus using Dunnett’s method of multiple comparisons with an overall type I error of 
0.05. The data shown are from three independent tests. Plaque assays to determine virus titer 
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were performed in duplicate, while qRT-PCR experiments were performed in triplicate for 
each independent test.
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Fig. 7. 
DEN2 prM-E trimer spike at neutral pH (PDB ID: 3C6D): (A) side view of the viral surface 
of the DEN2 prM-E trimer spike and (B) top view toward the viral surface. The E protein is 
shown in white, while the prM protein is shown in green. V19 is highlighted in yellow, T20 
is highlighted in orange, K31 is highlighted in red, L33 is highlighted in purple and the 
glycosylation site (labeled CHO) is highlighted in cyan.
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Table 2
Effect of hMAb binding to WNV IC mutant viruses with amino acid substitutions in pr.
pr AA substitution
in WNV-ICa
Fold change in human Ab titer with pr mutantsb
8G8 5G12 Human serac
WT prM 1.0 1.0 1.0
V19A 2.5 1.7 2.0
V19N 1.5 1.0 1.5
V19T 2.0 1.7 1.5
T20A 3.0 2.0 2.0
T20D 0.1 1.7 1.0
T20Q 1.5 1.3 1.0
T24A 1.3 1.5 1.3
K31A 5.0 2.7 1.2
K31T 2.7 2.0 2.0
K31V 4.0 2.0 2.0
L33A 2.0 2.0 1.3
L33K 2.0 2.0 1.3
L33Q 2.0 1.5 1.3
aAmino acid substitution at specific residue in the pr portion. Mutants in bold were previously determined to have a significant effect on VLP-
hMAb reactivity.
b
Four fold reduction or more (bold) in MAb endpoint titer of mutant viruses compared to WT was considered significant.
c
Human sera positive for anti-flavivirus antibody was used as control in ELISA to verify normalized viral protein concentrations.
Virology. Author manuscript; available in PMC 2018 February 14.
